Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;19(5):455-463.
doi: 10.1080/14760584.2020.1760097. Epub 2020 Apr 29.

Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies

Amy C Sherman  1 , David S Stephens  2
Affiliations
Review

Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies

Amy C Sherman et al. Expert Rev Vaccines. 2020 May.

Abstract

Introduction: For well over 100 years, meningococcal disease due to serogroup A Neisseria meningitidis (MenA) has caused severe epidemics globally, especially in the meningitis belt of sub-Saharan Africa.

Areas covered: The article reviews the background and identification of MenA, the global and molecular epidemiology of MenA, and the outbreaks of MenA in the African meningitis belt. The implementation (2010) of an equitable MenA polysaccharide-protein conjugate vaccine (PsA-TT, MenAfriVac) and the strategy to control MenA in sub-Saharan Africa is described. The development of a novel multi-serogroup meningococcal conjugate vaccine (NmCV-5) that includes serogroup A is highlighted. The PubMed database (1996-2019) was searched for studies relating to MenA outbreaks, vaccine, and immunization strategies; and the Neisseria PubMLST database of 1755 MenA isolates (1915-2019) was reviewed.

Expert opinion: Using strategies from the successful MenAfriVac campaign, expanded collaborative partnerships were built to develop a novel, low-cost multivalent component meningococcal vaccine that includes MenA. This vaccine promises greater sustainability and is directed toward global control of meningococcal disease in the African meningitidis belt and beyond. The new WHO global roadmap addresses the continuing problem of bacterial meningitis, including meningococcal vaccine prevention, and provides a framework for further reducing the devastation of MenA.

Keywords: Neisseria meningitidis; conjugate vaccine; immunization strategies; serogroup A.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Global epidemiology of meningococcal disease by serogroup, including serogroup A. Meningococcal serogroups are listed in the order of the estimated incidence (2010–2019) causing disease; however, in some areas, (*) data are quite limited. Serogroups are linked to 12 major genetic clonal complexes currently causing almost invasive meningococcal disease (modified from Stephens, DS, Neisseria meningitidis in Mandell, Douglas, Bennett Principles & Practices of Infectious Diseases, Bennett, Dolin, Blaser, eds.).
Figure 2.
Figure 2.
The meningitis belt of sub-Saharan Africa, from Meningococcal Disease, Chapter 4–2018 Yellow Book Centers for Disease Control and Prevention. Disease data source: World Health Organization. International Travel and Health. Geneva, Switzerland: 2012.
Figure 3.
Figure 3.
A summary of the meningitis task force goals and timeline, with a focus on Nm.
See this image and copyright information in PMC

References

    1. Stephens DS. Neisseria meningitidis. In: editor. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, updated edition,9th. Philadelphia, PA: Elsevier/Saunders; 2020. p. 2585–2607
    1. Viesseux M Memoire sur le maladie qui à regne à Genève au printemps de 1805. J Med Chir Pharmacol. 1805;11:243.
    1. Danielson L, Mann E. Letter to medical and agricultural registrar. Boston. 1806.
    1. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006. June;134(3):556–566. . - PMC - PubMed
    1. Cartwright KA, Stuart JM, Jones DM, et al. The Stonehouse Survey: nasopharyngeal Carriage of Meningococci and Neisseria Lactamica. Epidemiol Infect. 1987. December;99(3):591–601. . - PMC - PubMed

Publication types

MeSH terms